Table 5.
Author, year | Patients (n) | TP | FP | FN | TN | Follow-up (months) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | US CPPVa (%) | Clinical MCIHb (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Erez, 1996 | 200 | 38 | 2 | 0 | 160 | 36–48 | 100 | 98.8 | 95.0 | 100 | 20.0 | 19.0 |
Uno, 1992 | 32 | 4 | 1 | 0 | 27 | ≥ 12 | 100 | 96.4 | 80 | 100 | 15.6 | 12.5 |
Zaidi, 2017 | 287 | 39 | 6 | 13 | 229 | ≤ 24 | 75.0 | 97.4 | 86.7 | 94.6 | 15.7 | 18.1 |
TP true positive, FP false positive, FN false negative, TN true negative, PPV positive predictive value, NPV negative predictive value, US ultrasound, CPPV contralateral patent processus vaginalis, MCIH metachronous contralateral inguinal hernia
aAmount (%) of contralateral patent processus vaginalis as determined by ultrasonography
bAmount (%) of metachronous contralateral inguinal hernias that occurred during clinical follow-up